Achilles Therapeutics Selects Netrality’s 401 North Broad for United States Headquarters
March 01 2022 - 9:00AM
Netrality announced today that Achilles Therapeutics plc [NASDAQ:
ACHL], a clinical-stage biopharmaceutical company developing
precision T cell therapies to treat solid tumors, has leased 7,243
SF of lab space at 401 North Broad.
Achilles Therapeutics is
developing novel cancer immunotherapies targeting clonal
neoantigens: protein markers that are expressed on every cancer
cell’s surface. Achilles uses DNA sequencing data from each patient
and a proprietary bioinformatics platform to identify clonal
neoantigens specific to that patient to enable the development of
personalized cell therapies. The new lab space within 401 North
Broad will support research and development for T cell therapy.
“Netrality is excited to
welcome Achilles Therapeutics to Philadelphia’s hub for innovation,
technology, and creativity,” said Gerald M. Marshall, President and
CEO of Netrality Data Centers. “Achilles joins a flourishing
ecosystem of life sciences, tech, and other cutting-edge companies
reliant on mission-critical infrastructure within 401 North Broad.
The expansive growth of Philadelphia’s life sciences market has
been a game-changer for Netrality, as 401 North Broad exceeds the
foundational elements needed for optimal lab space.”
“We are pleased to expand
our global presence with our first United States facility in
Philadelphia. 401 North Broad offers access to the growing cell
therapy ecosystem and is well suited to meet the scope of our U.S.
R&D needs,” said Dr. Iraj Ali, Chief Executive Officer at
Achilles Therapeutics.
Achilles Therapeutics
joins Biomeme and NeuExcell Therapeutics at 401 North Broad, which
is quickly becoming a critical life sciences hub within the
Philadelphia market. 401 North Broad features heavy floor loading,
wide column spacing, high ceilings, backup power, secure loading
docks, and robust network connectivity. The building spans 11
stories and 1.3 million square feet with amenities that include
event spaces, conference rooms, modernized freight elevators,
secure on-site parking, and a bike room with direct access to the
bike lanes on 13th Street and Spring Garden Street.
“Following our recent
signing with Biomeme, Achilles Therapeutics’ selection of 401 North
Broad is another huge success for the building,” said Christian
Dyer, First Vice President at CBRE. “Achilles’ decision to build
their first United States lab and office space at 401 speaks
volumes about the building’s infrastructure, fantastic North Broad
location, and our commitment to life sciences.”
Philadelphia's life
sciences market continues its growth as a nexus for medical and
scientific innovation. According to CBRE’s Q4 2021 Life Sciences
Report, life sciences firms in the region raised over $2.1 billion
in VC and NIH funding in 2021, second only to 2019’s $2.2 billion.
Netrality has leased over 50,000 SF of lab space in 2021 at 401
North Broad. A 5,000 SF spec lab will be delivered in Q1 2022, and
an additional 50,000 SF of lab space is available within the
building.
CBRE’s Christian Dyer
represented Netrality and CBRE’s Matthew Knowles and Anthony Pell
represented Achilles during negotiations. To learn more about
leasing opportunities at 401 North Broad, visit
401northbroad.com.
About Achilles
TherapeuticsAchilles is a clinical-stage biopharmaceutical
company developing precision T cell therapies targeting clonal
neoantigens: protein markers unique to the individual that are
expressed on the surface of every cancer cell. The Company has two
ongoing Phase I/IIa trials, the CHIRON trial in patients with
unresectable locally advanced and metastatic non-small cell lung
cancer (NSCLC) and the THETIS trial in patients with recurrent or
metastatic melanoma. Achilles uses DNA sequencing data from each
patient, together with its proprietary PELEUS™ bioinformatics
platform, to identify clonal neoantigens specific to that patient,
and then develop precision T cell-based product candidates
specifically targeting those clonal neoantigens.
About Netrality
Data CentersNetrality owns and operates strategic
interconnected data centers and Meet Me Rooms, providing a mix of
colocation, and powered shell and wholesale data center solutions
driven by fiber-dense, network-rich interconnection environments.
Today, Netrality’s eighteen properties span 3.3 million square feet
and over 100 megawatts of capacity across North America.
Well-capitalized with a
long-term investment from Macquarie Asset Management, Netrality is
the largest privately held owner-operator of core interconnection
facilities in the United States. Netrality acquires strategically
located, core network interconnection data centers that power
latency-sensitive businesses, increase network resiliency, and
ensure always-on access to mission-critical applications. For more
information: www.netrality.com, LinkedIn, Twitter.
Media Contact:Caitlin BoydVP,
Marketingcboyd@netrality.com
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Sep 2023 to Sep 2024